Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

Chikungunya outbreaks have been reported in Brazil since 2014. Adolescents are a sensitive population who would benefit from a prophylactic vaccine. This study assessed the immunogenicity and safety of the vaccine VLA1553 in adolescents in Brazil. With an overall trial duration of 12 months, we now...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2024-09
Main Authors: Buerger, Vera, Hadl, Sandra, Schneider, Martina, Schaden, Michaela, Hochreiter, Romana, Bitzer, Annegret, Kosulin, Karin, Mader, Robert, Zoihsl, Oliver, Pfeiffer, Andrea, Loch, Ana Paula, Morandi, Eolo, Nogueira, Mauricio Lacerda, de Brito, Carlos Alexandre Antunes, Croda, Julio, Teixeira, Mauro Martins, Coelho, Ivo Castelo-Branco, Gurgel, Ricardo, da Fonseca, Allex Jardim, de Lacerda, Marcus Vinícius Guimarães, Moreira, Edson Duarte, Veiga, Ana Paula Rocha, Dubischar, Katrin, Wressnigg, Nina, Eder-Lingelbach, Susanne, Jaramillo, Juan Carlos
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chikungunya outbreaks have been reported in Brazil since 2014. Adolescents are a sensitive population who would benefit from a prophylactic vaccine. This study assessed the immunogenicity and safety of the vaccine VLA1553 in adolescents in Brazil. With an overall trial duration of 12 months, we now report data on safety and immunogenicity over a period of 28 days after vaccination. In this double-blind, randomised, placebo-controlled phase 3 trial, adolescents aged 12 to
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(24)00458-4